RT Journal Article
T1 Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.
A1 Dupont, Liane
A1 Snell, Luke B
A1 Graham, Carl
A1 Seow, Jeffrey
A1 Merrick, Blair
A1 Lechmere, Thomas
A1 Maguire, Thomas
A1 Hallett, Sadie R.
A1 Pickering, Suzanne
A1 Charalampous, Themoula
A1 Alcolea-Medina, Adela
A1 Huettner, Isabella
A1 Jimenez-Guardeño, Jose Manuel
A1 Acors, Sam
A1 Almeida, Nathalia
A1 Cox, Daniel
A1 Dickenson, Ruth
A1 Galao, Rui Pedro
A1 Kouphou, Neophytos
A1 Lista, Maria Jose
A1 Ortega-Prieto, Ana María
A1 Wilson, Harry D
A1 Winstone, Helena
A1 Fairhead, Casssandra
A1 Su, Jia Zhe
A1 Nebbia, Gaia
A1 Batra, Rahul
A1 Neil, Stuart JD
A1 Shankar-Hari, Manu
A1 Edgeworth, Jonathan D
A1 Malim, Michael H.
A1 Doores, Katie J
K1 COVID-19 - Aspectos moleculares
K1 Virología
AB COVID-19 vaccine design and vaccination rollout need to take into account a detailed understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 and emerging variants of concern (VOCs). Analyses of convalescent sera provide unique insights into antibody longevity and cross-neutralizing activity induced by variant spike proteins, which are putative vaccine candidates. Using sera from 38 individuals infected in wave 1, we show that cross-neutralizing activity can be detected up to 305 days pos onset of symptoms, although sera were less potent against B.1.1.7 (Alpha) and B1.351 (Beta). Over time, despite a reduction in overall neutralization activity, differences in sera neutralization potency against SARS-CoV-2 and the Alpha and Beta variants decreased, which suggests that continued antibody maturation improves tolerance to spike mutations. We also compared the cross-neutralizing activity of wave 1 sera with sera from individuals infected with the Alpha, the Beta or the B.1.617.2 (Delta) variants up to 79 days post onset of symptoms. While these sera neutralize the infecting VOC and parental virus to similar levels, cross-neutralization of different SARS-CoV-2 VOC lineages is reduced. These findings will inform the optimization of vaccines to protect against SARS-CoV-2 variants.
PB Nature Research
YR 2021
FD 2021
LK https://hdl.handle.net/10630/38191
UL https://hdl.handle.net/10630/38191
LA eng
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 21 ene 2026